Goldman Sachs
ZVSA

Goldman Sachs’s ZyVersa Therapeutics ZVSA Stock Holding History

Goldman Sachs’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-296
Closed -$200K – 6123
2023
Q1 		$200K Buy
296
+112
+61% +$83.8K ﹤0.01% 5304
2022
Q4 		$101K Buy
+184
New +$537K ﹤0.01% 5477

Other funds holding ZVSA

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Goldman Sachs's ZVSA Position: Q2 2023 in Review

Goldman Sachs sold out of ZyVersa Therapeutics (ZVSA) in Q2 2023, closing a stake of 296 shares — an estimated $200K sold.

Goldman Sachs first reported a position in ZVSA in Q4 2022 and held it in 2 quarters. The position peaked at $200K in Q1 2023. 9 funds tracked by Wall St. Rank hold ZVSA as of Q2 2023.

  • Goldman Sachs reported no remaining ZyVersa Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 296 ZyVersa Therapeutics shares in Q2 2023, an estimated $200K.
  • Goldman Sachs first reported a position in ZyVersa Therapeutics in Q4 2022 and held it in 2 quarters.
  • Goldman Sachs's ZyVersa Therapeutics position peaked at $200K in Q1 2023.
  • 9 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.